Junshi Biosciences Announces Inclusion of Toripalimab in The China National Reimbursement Drug List
[December 28, 2020] Junshi Biosciences Announces Inclusion of Toripalimab in The China National Reimbursement Drug List SHANGHAI, China, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, is pleased to announce that toripalimab has been included in the updated National Reimbursement Drug List (NRDL) (2020 Edition) for the treatment of melanoma by the China National Healthcare Security Administration (NHSA). The primary drug format specif...